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	 This	study	aimed	at	the	development	of	simple	and	cheap	conductometric	method	that	canbe	 used	 for	 the	 determination	 of	 naproxen	 in	 bulk	 and	 dosage	 forms.	 During	 the	 study,
naproxen	was	titrated	with	sodium	hydroxide	(Method	A)	and	potassium	hydroxide	(Method
B)	 and	 the	 end	 points	were	 determined	with	 conductivity	 cell.	 Variables	 affecting	 the	 end
point	 determination	 were	 also	 studied	 in	 the	 range	 of	 1‐10	 mg/mL	 of	 naproxen.	 The
proposed	 methods	 were	 validated	 by	 precision	 and	 recovery	 studies.	 The	 percentage
recoveries	ranged	from	99.15±0.659	and	101.13±0.543	with	%	RSD	of	0.897	and	0.749	with
sodium	 hydroxide	 and	 potassium	 hydroxide,	 respectively.	 The	 methods	 were	 effectively
applied	for	the	determination	of	naproxen	in	tablet	dosage	form.	The	methods	proposed	in
this	 study	 can	 be	 used	 as	 substitute	 for	more	 composite	 and	 classy	methods	 used	 for	 the
determination	 of	 naproxen	 and	 are	 highly	 reproducible	 as	 compared	 to	 other	 reported
methods.	
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1.	Introduction	
	
Naproxen	 ((2S)‐2‐(6‐methoxynaphthalen‐2‐yl)propanoic	
acid,	 Figure	 1),	 a	 nonsteroidal	 anti‐inflammatory	 drug	
(NSAID),	 is	 an	 arylalkylpropanoic	 acid	derivative	 and	 is	used	
for	the	treatment	of	rheumatoid	arthritis	and	other	rheumatic	
disease,	 dysmenorrhea,	 and	 acute	 gout	 [1,2].	 It	 is	 a	 potent	
cyclooxygenase	 inhibitor	 thereby	decreasing	the	 formation	of	
prostaglandins	 and	 thromboxanes	 [3].	 It	 also	 inhibits	 the	
enzyme	 thromboxane	synthase	 causing	 inhibition	 of	 the	
platelet	aggregation	process	[4].	
	
		
Figure	1.	Chemical	structure	of	naproxen.	
	
Naproxen	 is	 determined	 in	 bulk	 and	 pharmaceutical	
dosage	forms	by	UV	spectrophotometric	techniques	[5,6],	TLC	
[7],	 HPLC	 with	 UV	 detection	 methods	 [8],	 GC‐MS	 [9],	 ion‐
selective	 methods	 [10],	 phosphorescence	 and	 chemilumi‐
nescence	 methods	 [11],	 spectrofluorimetric	 techniques	 [12‐
14]	and	capillary	electrophoresis	with	mass	detectors	[15‐17].	
Bio‐analytical	 methods	 for	 detection	 of	 naproxen	 and	 its	
metabolites	 have	 also	 been	 reported	 [8].	 Most	 of	 the	
aforementioned	techniques	are	time‐consuming,	involve	costly	
and	 complicated	 instruments	 and	 therefore	 are	 not	 suitable	
for	routine	analysis.		
For	 quality	 control	 purposes,	 conductometric	 titrations	
serve	as	an	extremely	useful	method	and	can	be	widely	used	
for	 determination	 of	 pharmaceuticals	 [18‐20].	Measurements	
of	 conductivity	of	 the	 solutions	 can	be	used	 to	 estimate	 total	
number	of	ions	present	in	a	solution.	Conductometric	methods	
have	 proved	 to	 be	 cost	 effective	 for	 the	 assay	 of	 pharma‐
ceuticals	 in	 bulk	 and	 dosage	 forms	 because	 these	 offer	 the	
advantages	 of	 reasonable	 selectivity,	 fast	 response	 time,	
applicability	 to	 coloured	 and	 turbid	 solutions.	 However,	 no	
direct	 method	 utilising	 the	 concept	 of	 conductometric	 end	
point	 detection	 of	 naproxen	 has	 been	 reported	 in	 the	
literature.	Therefore,	the	present	work	is	aimed	at	finding	and	
elaborating	 conditions	 for	 conductometric	 determination	 of	
naproxen.	Earlier	also	the	authors	have	described	the	accurate	
and	precise	determination	of	losartan	potassium,	pantoprazole	
sodium,	sumatriptan	succinate,	rabeprazole	sodium	and	lome‐
floxacin	 hydrochloride	 (by	 using	 precipitating	 agents)	 [21],	
diphenhydramine	hydrochloride	(by	using	silver	nitrate)	[22]	
and	 pioglitazone	 hydrochloride	 (by	 acid‐base	 titrations)	 [23]	
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in	 bulk	 and	 pharmaceutical	 dosage	 forms	 by	 conductometric	
titrations.	 Therefore,	 in	 continuation,	 the	 present	 study	 was	
undertaken	 to	 hold	 a	 good	 future	 for	 routine	 analysis	 of	
naproxen	in	poor	resource	settings.	
	
2.	Experimental	
	
2.1.	Chemicals	and	reagents	
	
All	 chemicals	used	were	of	 analytical	 reagent	 grade	 from	
Sigma‐Aldrich.	 For	 preparing	 solutions,	 double	 distilled	
conductivity	 water	 was	 used.	 Sodium	 hydroxide,	 potassium	
hydroxide,	 phenolphthalein,	 oxalic	 acid	 and	 methanol	 were	
obtained	 from	 Merck,	 Germany.	 The	 authentic	 naproxen	
sample	was	obtained	as	 a	 gift	 from	Exela	Pharmsci.	 Pvt.	Ltd.,	
Egypt.	 2×10‐4	 M	 NaOH	 and	 2×10‐3	 M	 KOH	 solutions	 were	
freshly	 prepared	 with	 bi‐distilled	 water	 and	 standardized	
against	oxalic	acid.		
	
2.2.	Pharmaceutical	formulations	
	
Tablets	 of	 Riaproxen®	 (500	 mg),	 Proxen®	 (500	 mg)	 and	
Naprox	 DS®	 (250	mg)	 were	 procured	 from	 the	 local	 market	
(Jazan,	Kingdom	of	Saudi	Arabia).	
	
2.3.	Instrumentation	
	
Jenway	 470	model	 portable	 conductivity/TDS	meter	was	
used	for	all	conductometric	determinations.		
	
2.4.	Standard	solution	
	
The	stock	solution	of	1	mg/mL	was	prepared	by	dissolving	
100	 mg	 of	 standard	 naproxen	 in	 75	 mL	 of	 methanol	
(previously	 neutralised	 with	 phenolphthalein).	 The	 final	
volume	was	made	to	100	mL	with	bi‐distilled	water.		
	
2.5.	General	procedures	
	
2.5.1.	Conductometric	titration	
	
Into	 a	 100	mL	 calibrated	 flask,	 aliquots	 of	 standard	 drug	
solution	containing	1‐10	mg	of	naproxen	were	transferred	and	
final	volume	made	to	100	mL	with	a	mixture	of	methanol:	bi‐
distilled	water	 (3:1,	 v:v)	 and	 continued	 as	per	 the	procedure	
mentioned	in	method	A	and	method	B.	
	
2.5.1.1.	Method	A	
	
In	 method	 A,	 the	 contents	 as	 obtained	 from	 above	 were	
transferred	 to	 a	 conductivity	 cell	 and	 titrated	with	 2×10‐4	M	
NaOH	solution.	The	conductance	was	measured	after	each	0.1	
mL	addition	of	titrant	with	stirring	for	30	seconds.	The	correc‐
ted	 conductance	 values	 for	 each	 dilution	 were	 calculated	 as	
per	the	standard	reported	procedure	[23,24].	
	
2.5.1.2.	Method	B	
	
In	 method	 B,	 the	 contents	 as	 obtained	 from	 above	were	
transferred	 to	 a	 conductivity	 cell	 and	 titrated	with	 2×10‐3	M	
KOH	solutions.	The	conductance	was	measured	after	each	0.1	
mL	addition	of	titrant	with	stirring	for	30	seconds.	The	correc‐
ted	 conductance	 values	 for	 each	 dilution	 were	 calculated	 as	
per	the	standard	reported	procedure	[23,24].	
Equation	 (1)	was	 used	 for	 correction	 of	 conductance	 for	
dilution	[25].	
	
Ω‐1Correct	=	Ω‐1Obs	[v1+v2/v1]		 	 	 	 (1)	
	
where,	 Ω‐1Correct	 and	 Ω‐1Obs	 are	 the	 corrected	 electrolytic	
conductivity	 and	 the	 observed	 electrolytic	 conductivity,	 res‐
pecttively,	v1	represents	 the	 initial	volume	and	v2	represents	
the	 volume	 of	 NaOH	 and	 KOH	 added	 [26].	 The	 equivalence	
point	was	determined	by	plotting	a	 graph	between	corrected	
conductivity	and	volume	of	NaOH	and	KOH	added	for	Method	
A	and	Method	B,	respectively.	
A	 plot	 of	 corrected	 conductivity	 versus	 the	 volume	 of	
added	 NaOH	 and	 KOH	 was	 constructed	 and	 the	 equivalence	
point	 was	 determined.	 The	 percentage	 drug	 content	 was	
determined	by	the	formula	given	in	Equation	(2),	
	
Amount	(mg)	=	V×M×R/N	 		 	 	 (2)	
	
where,	V	is	the	volume	of	titrant,	M	is	molecular	weight	of	the	
drug,	R	is	molar	concentration	of	NaOH	and	KOH,	respectively,	
and	N	is	number	of	moles	of	titrant	consumed	by	one	mole	of	
the	drug.	
	
2.5.2.	Procedure	for	formulations	
	
An	equivalent	amount	100	mg	of	powder	of	twenty	tablets	
each	of	Riaproxen®	500	mg,	Proxen®	500	mg	and	Naprox	DS®	
250	mg	were	 taken	 in	100	calibrated	 flasks.	To	each	 flask	75	
mL	 of	 methanol	 was	 added	 (previously	 neutralised	 with	
phenolphthalein	solution)	and	stirred	for	10	minutes.	The	final	
volume	 was	 made	 up	 to	 100	 mL	 with	 bi‐distilled	 water.	 All	
solutions	 were	 filtered	 through	 0.45	 μm	 filter.	 The	 suitable	
aliquots	 were	 then	 analysed	 for	 their	 percentage	 purity	 by	
following	the	procedure	given	in	conductometric	titrations.	
	
2.5.3.	Reference	method	
	
The	 procedure	 given	 in	 USP‐31	 is	 used	 as	 a	 reference	
method	and	used	is	for	comparison	of	results	[27].		
	
3.	Results	and	discussion	
	
Various	 ionic	 solutions	 wherein	 there	 is	 a	 significant	
change	 in	 the	 conductance	 values	 during	 the	 end	 point,	
conductometric	 measurements	 can	 be	 used	 for	 their	
quantitative	 analysis.	 Conductometric	 titrations	 depend	
mainly	on	all	the	ionic	species	that	will	be	present	during	the	
titration.	 Secondary	 factors	 affecting	 the	process	 include	 ion‐
ion	 association,	 ion‐solvent	 interactions,	 temperature,	
viscosity,	 dielectric	 constant	 and	 proton	 transfer	 species	 etc.	
[24,25].	Conductivity	of	a	solution	can	be	defined	as	ability	of	a	
solution	to	pass	an	electric	current	and	depends	on	a	number	
of	 factors	 such	 as	 concentration,	mobility	 of	 ions,	 valence	 of	
ions	 and	 temperature.	 The	 conductivity	 can	 be	 calculated	 by	
the	Equation	(3):	
	
κ	=	G	•	K	 	 	 	 	 	 (3)	
	
where,	κ	=	Conductivity	(S/cm);	G	=	Conductance	(S),	where	G	
=	1/R;	and	K	=	Cell	constant	(cm‐1).	
Generally	conductivity	of	solutions	is	measured	in	aqueous	
solutions	 because	 water	 by	 the	 process	 of	 solvation	 can	
stabilise	 the	 ions	 formed.	 Pharmaceutical	 substances	 can	
behave	 as	 electrolytes	 and	 include	 acids,	 bases	 and	 salts	 and	
can	 be	 either	 strong	 or	 weak.	 Strong	 electrolytes	 are	
substances	 that	 are	 fully	 ionised	 in	 solution.	 Solutions	 of	
strong	electrolytes	conduct	electricity	because	the	positive	and	
negative	 ions	 can	 migrate	 largely	 independently	 under	 the	
influence	of	an	electric	field.	Weak	electrolytes	are	substances	
that	 are	 not	 fully	 ionised	 in	 solution.	 A	 solution	 of	 a	 weak	
electrolyte	can	conduct	electricity,	but	usually	not	as	well	as	a	
strong	 electrolyte	 because	 there	 are	 fewer	 ions	 to	 carry	 the	
charge	from	one	electrode	to	the	other.	
Organic	acids	having	a	pKa	ranging	from	4.0	to	5.5	can	be	
titrated	with	inorganic	bases	such	as	sodium	hydroxide	(at	low	
concentrations),	 lithium	hydroxide	 (in	presence	of	 ammonia)	
[28],	as	well	as	organic	bases	such	as	potassium	methoxide	in		
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Figure	2.	Simple	chemical	reactions	between	naproxen	and	two	bases,	sodium	hydroxide	(Method	A)	and	potassium	hydroxide	(Method	B)	
	
	
pyridine‐benzene	 or	 tetramethylammonium	 hydroxide	 in	
benzene,	with	intersection	angles	as	satisfactory	as	those	given	
by	 strong	 acids	 [29].	 Naproxen	 having	 one	 carboxylic	 acid	
group	with	pKa	value	of	4.15	[2]	serves	as	a	suitable	candidate	
for	conductometric	titration.	
Conductance	measurements	were	used	successfully	in	our	
studies	 in	 the	 quantitative	 titration	 of	 naproxen	 as	 the	
conductance	 of	 naproxen	 solution	 varies	 significantly	 before	
and	 after	 the	 equivalence	 point.	 The	 point	 of	 intersection	 of	
two	lines	was	taken	as	the	end	point.	
The	 molecular	 structure	 of	 naproxen	 and	 its	 possible	
chemical	 reaction	 with	 sodium	 hydroxide	 and	 potassium	
hydroxide	has	been	depicted	in	Figure	2.		
Different	conductometric	titration	curves	obtained	during	
the	 studies	 of	 pure	 naproxen	 in	 bulk	 and	 tablet	 dosage	 form	
have	been	depicted	in	Figure	3‐6.	The	trends	obtained	could	be	
compared	 with	 the	 representative	 curves	 of	 weak	 acid	 and	
strong	base	titrations.	
	
0
5
10
15
20
25
30
35
0 1 2 3 4 5 6 7 8
C
on
du
ct
iv
ity
(μS
/c
m
)
VNaOH (mL) 		
Figure	3.	Conductometric	titration	curve	of	naproxen	with	2×10‐4	M	NaOH.	
	
Initially,	the	high	conductance	values	of	naproxen	solution	
could	 be	 attributed	 to	 the	 high	 conductivity	 of	 its	 H+	 ions	
(349.82).	 However,	 during	 the	 titration	 high	 conductivity	 H+	
ions	(349.82)	of	naproxen	were	replaced	by	 low	conductivity	
Na+	 ions	 (50.11)	 of	 sodium	hydroxide	 and	K+	 ions	 (73.52)	 of	
potassium	 hydroxide	 indicating	 the	 slight	 decrease	 in	 the	
conductivity	 of	 the	 solution.	 This	 result	 in	 little	 change	 in	
conductivity	with	respect	to	the	volume	of	base	added.	During	
the	titration	of	naproxen	with	sodium	or	potassium	hydroxide,	
the	salt	(sodium	or	potassium	salt	of	naproxen	with	Method	A	
and	 Method	 B,	 respectively)	 tends	 to	 limit	 ionisation	 of	
naproxen	still	present	so	 that	 its	 conductance	decreases.	The	
rising	 salt	 concentration	 however	 will	 tends	 to	 produce	 an	
increase	 in	 conductance.	 As	 a	 result	 of	 these	 opposing	
influences	the	titration	curves	show	a	minima	depending	upon	
the	concentration	and	strength	of	naproxen.	The	conductance	
values	 near	 the	 equivalence	 point	 are	 high	 because	 of	 the	
hydrolysis	 of	 the	 respective	 salts.	 The	 initial	 change	 in	
conductivity	 values	 can	 also	 be	 attributed	 to	weakly	 basic	 of	
nature	 of	 naproxen.	 This	 could	 be	 further	 justified	 as	 very	
dilute	 solutions	 of	 bases	 were	 used	 for	 the	 titrations.	 No	
significant	 differences	 in	 the	 shape	 of	 curves	were	 observed	
when	 naproxen	 was	 titrated	 with	 sodium	 hydroxide	 or	
potassium	hydroxide;	however	potassium	hydroxide	was	used	
in	 comparatively	 higher	 concentrations	 than	 the	 sodium	
hydroxide.	 After	 the	 end	point,	 a	 sudden	 increase	 in	 conduc‐
tance	 was	 observed.	 This	may	 be	 due	 to	 increase	 of	 ions	 of	
high	conductivity	such	as	OH‐	during	the	end	point.	
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Figure	4.	Conductometric	titration	curve	of	naproxen	with	2×10‐3 M	KOH.
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Figure	 5.	 Conductometric	 titration	 curve	 of	 Riaproxen®	 with	 2×10‐4 M	
NaOH.	
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Table	1.	Linear	regression	parameters	for	naproxen	determination	using	conductometric	titrations.	
Parameters		 NaOH	(Method	A) KOH	(Method	B) Reference	method	USP‐31	[27]
Optimum	concentration	range	of	naproxen	 1‐10	mg/mL 1‐10	mg/mL 1‐10	mg/mL	
Intercept	of	the	regression	line	 1.227	 1.231	 1.216	
Slope	of	regression	line	 0.993	 0.993	 0.994	
Student	t‐test	(2.310)	 1.837	 1.859	 2.106	
Range	of	error	(%)	 ±0.74 ±0.74 ±0.79
	
Table	2.	Accuracy	studies	(%	Recovery).	
Method	 Amount	taken	(mg/mL)	 Amount	added	(mg/mL)	 %	Recovery	 RSD%	
NaOH		
(Method	A)	
10	 8 99.5143±0.6163 0.4074
10	 10 99.1356±0.7033 0.4102
10	 12 99.2416±0.6995 0.3628
KOH	
(Method	B)	
10	 8 99.4513±0.7019 0.3052
10	 10	 98.9916±0.8896	 0.4136	
10	 12 99.3096±0.7012 0.4151
Reference	method	
USP‐31	[27]	
10	 8	 98.8396±0.8016	 0.3052	
10	 10 98.9316±0.7896 0.4136
10	 12 98.9011±0.8013 0.4151
	
Table	3.	Determination	of	naproxen	in	different	tablet	formulations.	
Drug	
Formulation	
Amount	of	drug	
(mg/mL)	
%	Drug	content	a	 Reference	method	 Mean	
RSD%	NaOH	 RSD% KOH RSD%
Riaproxen®		
(500	mg)	
6	 99.9580±0.7874	 0.4822	 99.7590±0.8173	 0.4723	 99.7910±0.6969	 0.4699	
8	 99.9280±0.1014 99.8990±0.1103 99.9240±0.1090	
10	 99.2970±1.1140 99.1980±1.1160 99.2920±1.1100	
Proxen®	
(500mg)	
6	 99.3231±0.7026	 0.4662	 99.2991±0.6926	 0.4665	 99.2991±0.6926	 0.4672	
8	 99.2241±0.7027 99.2264±0.7022 99.2264±0.7022	
10	 99.1641±0.7019 99.1642±0.7197 99.1642±0.7197	
Naprox	DS®	
(250	mg)	
6	 99.3231±0.7026 0.4662 99.3235±0.7029 0.4669 99.3235±0.7029	 0.4677
8	 99.2241±0.7027 99.2245±0.7030 99.2245±0.7030	
10	 99.1641±0.7019	 99.1646±0.7022	 99.1646±0.7022	
a	Five	independent	analyses	At	95%	confidence	level	t‐value	is	2.776	and	F‐value	is	6.26	(n	=	5,	p	˂	0.05,	t	=	2.677	and	F‐value	=	6.37).	
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Figure	 6.	 Conductometric	 titration	 curve	 of	 Riaproxen® with	 2×10‐3 M	
KOH.	
	
3.1.	Optimization	of	variables		
	
During	 the	 studies	 different	 variables	 to	 obtain	 the	
optimum	 conditions	 for	 performing	 the	 titration	 in	 a	
quantitative	manner	were	also	performed	and	are	as	follows.	
	
3.1.1.	Effect	of	solvent	used	
	
Different	 solvents	 such	 as	 methanol,	 ethanol,	 water	 and	
acetone	in	different	ratios	with	water	were	tried	to	obtain	the	
acceptable	 results.	 Preliminary	 investigations	 suggested	 that	
methanol	 and	 water	 in	 the	 ratio	 of	 3:1	 provide	 the	 most	
suitable	 conductometric	 titration	 curve.	 Ethanol:water	
mixture	 resulted	 in	 distorted	 curve	 shape	 proving	 that	 ionic	
mobility	was	 not	 proportional	 to	 the	 conductance	 and	 hence	
was	 not	 considered	 for	 the	 studies.	 When	 titration	 was	
continued	with	acetone:water	in	ratio	3:1,	the	solution	became	
turbid	 after	 base	 addition	 and	 unstable	 conductance	 values	
were	also	observed	for	other	ratios.		
	3.1.2.	Reagent	concentration	
	
Titrant	concentrations	ranging	from	2×10‐2	to	4×10‐4	M	of	
sodium	hydroxide	and	potassium	hydroxide	were	studied.	The	
optimum	concentration	of	2×10‐4	M	for	sodium	hydroxide	and	
2×10‐3	 M	 for	 potassium	 hydroxide	 was	 selected	 for	 further	
studies	based	on	stable	conductance	values.	
	
3.1.3.	Effect	of	temperature		
	
Preliminary	 investigations	 suggested	 that	 no	 significant	
change	 in	 conductance	 values	 were	 observed	 at	 20‐40	 °C.	
Therefore,	an	optimum	temperature	of	25	°C	was	selected	for	
further	studies.	
	
3.1.4.	Method	validation	
	
The	proposed	procedures	were	applied	and	validated	 for	
the	determination	of	naproxen	 in	pure	 and	 tablet	 forms.	The	
results	 are	 presented	 in	 Table	 1	 to	 5.	 Linear	 regression	
parameters	 for	 determination	 of	 naproxen	 using	 the	
conductometric	titration	methods	have	been	depicted	in	Table	
1.	The	percentage	recovery	for	accuracy	and	precision	studies	
was	determined	on	six	replicates	and	the	data	is	presented	in	
Table	2.	The	low	values	of	%RSD	indicated	that	the	method	to	
be	 precise	 and	 reproducible.	 The	 data	 from	 percentage	
recoveries	 also	 confirmed	 the	 accuracy	 of	 the	 proposed	
methods.	 Further,	 it	 could	 be	 concluded	 that	 the	 excipients	
present	in	the	tablets	did	not	interfere	with	the	determination	
of	 naproxen.	 The	 proposed	 methods	 when	 applied	 to	 the	
tablets	 of	 three	 brands	 also	 showed	 statistically	 significant	
results.	The	data	is	presented	in	Table	3.	The	suitability	of	the	
proposed	methods	 could	 be	 further	 ascertained	 by	 intra‐day	
precision	studies,	Table	4	and	5	on	different	days	and	different	
analysts.	 In	 all	 cases,	 the	 average	 results	 obtained	 by	
developed	 methods	 and	 official	 method	 were	 statistically	
identical,	as	the	difference	between	the	average	values	had	no	
significance	at	95%	confidence	level.	
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Table	4.	Precision	Studies	(Intra‐day	precision).	
Method	 Concentration	(mg/mL)	 %	Drug	Content RSD%	
NaOH	
(Method	A)	
6	 99.958±0.7976 0.4833	
8	 99.928±0.1064
10	 99.297±1.116	
KOH	
(Method	B)	
6	 99.4231±0.7028 0.4226	
8	 99.2941±0.7029	
10	 99.346±0.7019
	
Table	5.	Precision	Studies	(Intra‐day	precision).	
Method	 Analyst	 Concentration	(mg/mL) %	Drug	Content Mean	RSD
NaOH	(Method	A)	 Analyst	1	 10	 99.78	 0.5286	
KOH	(Method	B)	 Analyst	2	 10 99.88 0.5315	
	
	
4.	Conclusion	
	
Electroanalytical	 methods	 utilising	 the	 conductometric	
titrations	 offer	 a	 distinctive	 and	 rather	 simple	 approach	 for	
quantitative	 analysis	 of	 drugs	 in	 bulk	 and	 dosage	 forms.	 The	
proposed	 methods	 have	 shorter	 running	 time	 and	 do	 not	
require	 expertise	 like	 HPLC,	 GC,	 MS	 or	 other	 methods.	 The	
methods	 utilise	 cheap	 and	 commonly	 available	 reagents	 and	
chemicals	 and	 do	 not	 require	 special	 methods	 for	 sample	
preparation.	The	results	obtained	confirmed	the	methods	to	be	
simple,	sensitive,	accurate,	precise,	and	economical	and	can	be	
used	 in	 the	 determination	 of	 naproxen	 in	 bulk	 and	 dosage	
forms	in	a	routine	manner.	
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